Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Increases By 43.6%

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 6,620,000 shares, a growth of 43.6% from the March 15th total of 4,610,000 shares. Based on an average daily trading volume, of 2,120,000 shares, the days-to-cover ratio is presently 3.1 days. Currently, 8.2% of the shares of the stock are sold short.

Compass Therapeutics Price Performance

• Top 3 High-Momentum Companies Analysts Are Still Bullish On

NASDAQ CMPX traded up $0.05 on Friday, reaching $1.75. The stock had a trading volume of 692,766 shares, compared to its average volume of 859,566. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $4.08. The company has a market cap of $242.00 million, a P/E ratio of -4.73 and a beta of 1.40. The firm has a fifty day moving average of $2.41 and a two-hundred day moving average of $2.09.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Research analysts predict that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Insider Activity at Compass Therapeutics

In other news, Director Carl L. Gordon sold 3,571,428 shares of Compass Therapeutics stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jonathan Anderman purchased 20,000 shares of the business's stock in a transaction dated Monday, April 7th. The shares were purchased at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the purchase, the insider now directly owns 21,000 shares of the company's stock, valued at $32,340. This trade represents a 2,000.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 28.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Compass Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CMPX. SG Americas Securities LLC grew its position in Compass Therapeutics by 138.2% in the first quarter. SG Americas Securities LLC now owns 940,784 shares of the company's stock valued at $1,787,000 after acquiring an additional 545,767 shares during the last quarter. Simplicity Wealth LLC bought a new position in shares of Compass Therapeutics in the 1st quarter worth $88,000. Squarepoint Ops LLC acquired a new position in Compass Therapeutics during the fourth quarter worth $35,000. Tang Capital Management LLC lifted its position in Compass Therapeutics by 225.4% in the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock valued at $8,555,000 after acquiring an additional 4,087,005 shares in the last quarter. Finally, ProShare Advisors LLC boosted its position in shares of Compass Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock valued at $42,000 after buying an additional 9,451 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on CMPX shares. Leerink Partnrs raised Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 1st. D. Boral Capital restated a "buy" rating and issued a $32.00 price target on shares of Compass Therapeutics in a report on Tuesday, April 1st. Leerink Partners upgraded shares of Compass Therapeutics from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $4.00 to $6.00 in a report on Wednesday, April 2nd. HC Wainwright increased their price target on Compass Therapeutics from $10.00 to $24.00 and gave the company a "buy" rating in a research report on Friday, April 4th. Finally, Guggenheim reissued a "buy" rating and issued a $12.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, April 2nd. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $13.38.

Get Our Latest Report on Compass Therapeutics

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

Read More

• Five stocks we like better than Compass Therapeutics
• Where to Find Earnings Call Transcripts
• 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks
• Financial Services Stocks Investing
• These 3 Stocks Have Huge Last 12 Months Shareholder Yields
• How to Invest in Small Cap Stocks
• Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Compass Therapeutics Right Now?

Before you consider Compass Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.

While Compass Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here